Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
96-week comparison of atazanavir/ritonavir vs lopinavir/ritonavir with tenofovir-emtricitabine in treatment-naive HIV-1 infection
2005-001895-11Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of atazanavir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of subjects with HIV RNA < 50 copies/mL at Week 48. Started Nov 2005; status: completed.
02
Drugs
atazanavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-001895-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001895-11.